Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Table 1 Patient demographic and clinical characteristics

	Median; [IQR]	Number	(%)
Age (years)	60.5; [55.5–67.5]
- < 75		35	(97.2)
- ≥ 75		1	(2.8)
Gender
- M		22	(61.1)
- F		14	(38.9)
Site of recurrence/metastases
- Pelvis		27	(75)
- Liver		9	(25)
Presence of other metastases
- Yes		18	(50)
- No		18	(50)
Number of previous systemic chemotherapy lines
- 2		35	(97.2)
- > 2		1	(2.8)
KRAS, NRAS, BRAF genotype status
- KRAS exon 2 codon 12		3	(8.3)
- NRAS mutations		0	(0)
- BRAF mutations		0	(0)
- Unknown		13	(36.1)
SBTT (months)	16.0; [12–20.5]
ECOG
- 0		0	(0)
- 1		9	(25)
- 2		13	(36.1)
- 3		14	(38.9)
- 4		0	(0)
PFSTT (months)	7.5; [5–12.5]
OSTT (months)	34.0; [23.5–41.5]

IQR Interquartile range, SBTT Survival from recurrence/metastases date and first treatment of tailored intraarterial chemotherapy in association with targeted therapy, ECOG Eastern Cooperative Oncology Group performance status before first treatment of tailored intraarterial chemotherapy in association with targeted therapy, PFSTT Progression free survival after tailored therapy, OSTT Overall survival after tailored therapy, KRAS Kirsten rat sarcoma virus gene, NRAS Neuroblastoma RAS gene, BRAF v-Raf murine sarcoma viral oncogene homolog B

ISSN: 1471-2407